The high mobility group A1 molecular switch

Turning on cancer-can we turn it off?

Tait H. Huso, Linda M Smith Resar

Research output: Contribution to journalArticle

Abstract

Introduction: Emerging evidence demonstrates that the high mobility group A1 (HMGA1) chromatin remodeling protein is a key molecular switch required by cancer cells for tumor progression and a poorly differentiated, stem-like state. Because the HMGA1 gene and proteins are expressed at high levels in all aggressive tumors studied to date, research is needed to determine how to 'turn off' this master regulatory switch in cancer. Areas covered: In this review, we describe prior studies that underscore the central role of HMGA1 in refractory cancers and we discuss approaches to target HMGA1 in cancer therapy. Expert opinion: Given the widespread overexpression of HMGA1 in diverse, aggressive tumors, further research to develop technology to target HMGA1 holds immense promise as potent anticancer therapy. Previous work in preclinical models indicates that delivery of short hairpin RNA or interfering RNA molecules to 'switch off' HMGA1 expression dramatically impairs cancer cell growth and tumor progression. The advent of nanoparticle technology to systemically deliver DNA or RNA molecules to tumors brings this approach even closer to clinical applications, although further efforts are needed to translate these advances into therapies for cancer patients.

Original languageEnglish (US)
Pages (from-to)541-553
Number of pages13
JournalExpert Opinion on Therapeutic Targets
Volume18
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Tumors
Switches
Neoplasms
RNA
Molecules
Cell growth
Refractory materials
Small Interfering RNA
Chromatin
Proteins
Cells
Nanoparticles
Technology
DNA
Chromatin Assembly and Disassembly
Expert Testimony
Research
Therapeutics
Growth

Keywords

  • High mobility group A1
  • High mobility group A1 protein
  • Molecular switch
  • Therapeutic target
  • Tumor progression

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine
  • Medicine(all)

Cite this

The high mobility group A1 molecular switch : Turning on cancer-can we turn it off? / Huso, Tait H.; Smith Resar, Linda M.

In: Expert Opinion on Therapeutic Targets, Vol. 18, No. 5, 2014, p. 541-553.

Research output: Contribution to journalArticle

@article{ce40efc60c4940e7807802a5a655b560,
title = "The high mobility group A1 molecular switch: Turning on cancer-can we turn it off?",
abstract = "Introduction: Emerging evidence demonstrates that the high mobility group A1 (HMGA1) chromatin remodeling protein is a key molecular switch required by cancer cells for tumor progression and a poorly differentiated, stem-like state. Because the HMGA1 gene and proteins are expressed at high levels in all aggressive tumors studied to date, research is needed to determine how to 'turn off' this master regulatory switch in cancer. Areas covered: In this review, we describe prior studies that underscore the central role of HMGA1 in refractory cancers and we discuss approaches to target HMGA1 in cancer therapy. Expert opinion: Given the widespread overexpression of HMGA1 in diverse, aggressive tumors, further research to develop technology to target HMGA1 holds immense promise as potent anticancer therapy. Previous work in preclinical models indicates that delivery of short hairpin RNA or interfering RNA molecules to 'switch off' HMGA1 expression dramatically impairs cancer cell growth and tumor progression. The advent of nanoparticle technology to systemically deliver DNA or RNA molecules to tumors brings this approach even closer to clinical applications, although further efforts are needed to translate these advances into therapies for cancer patients.",
keywords = "High mobility group A1, High mobility group A1 protein, Molecular switch, Therapeutic target, Tumor progression",
author = "Huso, {Tait H.} and {Smith Resar}, {Linda M}",
year = "2014",
doi = "10.1517/14728222.2014.900045",
language = "English (US)",
volume = "18",
pages = "541--553",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - The high mobility group A1 molecular switch

T2 - Turning on cancer-can we turn it off?

AU - Huso, Tait H.

AU - Smith Resar, Linda M

PY - 2014

Y1 - 2014

N2 - Introduction: Emerging evidence demonstrates that the high mobility group A1 (HMGA1) chromatin remodeling protein is a key molecular switch required by cancer cells for tumor progression and a poorly differentiated, stem-like state. Because the HMGA1 gene and proteins are expressed at high levels in all aggressive tumors studied to date, research is needed to determine how to 'turn off' this master regulatory switch in cancer. Areas covered: In this review, we describe prior studies that underscore the central role of HMGA1 in refractory cancers and we discuss approaches to target HMGA1 in cancer therapy. Expert opinion: Given the widespread overexpression of HMGA1 in diverse, aggressive tumors, further research to develop technology to target HMGA1 holds immense promise as potent anticancer therapy. Previous work in preclinical models indicates that delivery of short hairpin RNA or interfering RNA molecules to 'switch off' HMGA1 expression dramatically impairs cancer cell growth and tumor progression. The advent of nanoparticle technology to systemically deliver DNA or RNA molecules to tumors brings this approach even closer to clinical applications, although further efforts are needed to translate these advances into therapies for cancer patients.

AB - Introduction: Emerging evidence demonstrates that the high mobility group A1 (HMGA1) chromatin remodeling protein is a key molecular switch required by cancer cells for tumor progression and a poorly differentiated, stem-like state. Because the HMGA1 gene and proteins are expressed at high levels in all aggressive tumors studied to date, research is needed to determine how to 'turn off' this master regulatory switch in cancer. Areas covered: In this review, we describe prior studies that underscore the central role of HMGA1 in refractory cancers and we discuss approaches to target HMGA1 in cancer therapy. Expert opinion: Given the widespread overexpression of HMGA1 in diverse, aggressive tumors, further research to develop technology to target HMGA1 holds immense promise as potent anticancer therapy. Previous work in preclinical models indicates that delivery of short hairpin RNA or interfering RNA molecules to 'switch off' HMGA1 expression dramatically impairs cancer cell growth and tumor progression. The advent of nanoparticle technology to systemically deliver DNA or RNA molecules to tumors brings this approach even closer to clinical applications, although further efforts are needed to translate these advances into therapies for cancer patients.

KW - High mobility group A1

KW - High mobility group A1 protein

KW - Molecular switch

KW - Therapeutic target

KW - Tumor progression

UR - http://www.scopus.com/inward/record.url?scp=84906329685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906329685&partnerID=8YFLogxK

U2 - 10.1517/14728222.2014.900045

DO - 10.1517/14728222.2014.900045

M3 - Article

VL - 18

SP - 541

EP - 553

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 5

ER -